[
  {
    "ts": null,
    "headline": "InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors",
    "summary": "MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta",
    "url": "https://finnhub.io/api/news?id=cbf4086be922fe40af76baad2fa8ecc9c9a55cc486f6ca9abd74ada5f5e3cc01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732568700,
      "headline": "InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors",
      "id": 131635808,
      "image": "https://media.zenfs.com/en/globenewswire.com/a4275cd4d1570a94e15e50c2e3dbb7b6",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta",
      "url": "https://finnhub.io/api/news?id=cbf4086be922fe40af76baad2fa8ecc9c9a55cc486f6ca9abd74ada5f5e3cc01"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=d7cddf97c11fe9ad633163a1da98bd6137a141d52d892b5748307ef3e526f379",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552560,
      "headline": "Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains",
      "id": 131637561,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=d7cddf97c11fe9ad633163a1da98bd6137a141d52d892b5748307ef3e526f379"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis",
    "summary": "Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical developm",
    "url": "https://finnhub.io/api/news?id=c53309253782c60d766affcc181786325ad96a237bbe784168b79a4701687fef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732536000,
      "headline": "Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis",
      "id": 131651931,
      "image": "https://media.zenfs.com/en/prnewswire.com/f7ffa3a72ae8112c7f49c6d8d2b16d31",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical developm",
      "url": "https://finnhub.io/api/news?id=c53309253782c60d766affcc181786325ad96a237bbe784168b79a4701687fef"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories: Investors Should Wait For A Pullback",
    "summary": "Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need to be patient with ABT stock.",
    "url": "https://finnhub.io/api/news?id=2d8b6b2ed9e92d8a824671b3752a721a713f5051c68ca614524c304714cdc079",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732493875,
      "headline": "Abbott Laboratories: Investors Should Wait For A Pullback",
      "id": 131620960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399813281/image_1399813281.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need to be patient with ABT stock.",
      "url": "https://finnhub.io/api/news?id=2d8b6b2ed9e92d8a824671b3752a721a713f5051c68ca614524c304714cdc079"
    }
  }
]